Richard M. Lush

<i>All-trans</i>-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Noweeda Mirza, Mayer Fishman, Ingo Fricke et al. · Cancer Research · 2006 · 549 citations · Full text

All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

Sergei Kusmartsev, Fengdong Cheng, Bin Yu et al. · PubMed · 2003 · 461 citations

Cell Therapy, Immunology, Immunoediting +19

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann et al. · Journal of Clinical Oncology · 2001 · 294 citations

Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study

Pamela N. Münster, Douglas C. Marchion, Elona Biçaku et al. · Journal of Clinical Oncology · 2007 · 218 citations · Full text